Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., reported dosing of the first patient in an investigator sponsored phase II proof-of-concept trial of the company's oral cyclin dependent kinase inhibitor seliciclib in Cushing's disease (CD). Clinicians at Cedars-Sinai, Los Angeles, were awarded a grant from the National Institute of Diabetes and Digestive and Kidney Diseases to evaluate seliciclib, which Cyclacel is evaluating in cancer, as a potential therapy for the disease.